Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day
Zymeworks Reports Preliminary Phase 1 Trial Results For Zanidatamab Zovodotin (ZW49) At European Society For Medical Oncology Annual Congress
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results
Zymeworks Announces Participation In Upcoming Investor Conferences
Zymeworks Announces Oral Presentation Of Data From Phase 1 Study Of Zanidatamab Zovodotin (ZW49) In Solid Cancers At European Society For Medical Oncology (ESMO) Congress 2022 In Paris
Zymeworks To Host Second Quarter Results Conference Call
Zymeworks Statement on U.S. Supreme Court Overturning Roe v. Wade
Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer
Zymeworks Announces Participation In Upcoming Investor Conference
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Zymeworks Announces Presentations At 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting
Zymeworks To Host First Quarter 2022 Results Conference Call
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
Zymeworks To Host Fourth Quarter And Full Year 2021 Results Conference Call
Zymeworks Provides Corporate Update On Key Strategic Priorities And Outlook For 2022
Zymeworks To Present At 40th Annual J.P. Morgan Healthcare Conference
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
Zymeworks Announces Second Janssen Bispecific Antibody To Begin Clinical Development Utilizing Azymetric™ And EFECT™ Therapeutic Platforms
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Mediacorp Recognizes Zymeworks as One of Canada’s 2022 Top 100 Employers
Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
Zymeworks-GSK Collaboration Leads To Design and Validation of a Novel Engineered, FcγRIIb-Selective Fc Platform for Therapeutic Antibody Development
November is Stomach Cancer Awareness Month
Zymeworks Shares Perspective on the Promise of Multi-Specific Antibodies at Digital STAT News Event
Zymeworks Announces Webcast To Present HERIZON-GEA-01 Pivotal Trial Design And Zanidatamab Commercial Strategy In Gastrointestinal Cancers
Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate And Durability In First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) At The European Society For Medical Oncology (ESMO) Annual Congress
Cholangiocarcinoma Foundation (CCF) Launches Program to Support Newly Diagnosed Patients and Their Caregivers
Great Place to Work Canada Names Zymeworks Among 2021 Best Workplaces™ In Healthcare
Zymeworks Announces Abstract For Zanidatamab In First-Line HER2-Expressing Gastroesophageal Cancers (GEA) At The European Society For Medical Oncology (ESMO) Annual Congress
Zymeworks Recognized Among Canada’s 2021 Best Workplaces™ for Giving Back
Zymeworks Reports 2021 Second Quarter Financial Results
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
Zymeworks Team Carries the Journey of Hope Torch to Hope, Canada
Zymeworks Supports Dave’s 15,000 Mile Journey of Hope
Zymeworks to Present at Jefferies Virtual Healthcare Conference
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
FDA Clears Zanidatamab Phase 3 Pivotal Trial in First Line HER2-positive Gastroesophageal Adenocarcinoma
Zymeworks Reports 2021 First Quarter Financial Results
Zymeworks to Present at Bloom Burton Healthcare Conference
Zymeworks Introduces Fourth Therapeutic Platform, ProTECT™
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Congratulations to Zymeworks Scientist Anna von Rossum, Healthcare Business Women’s Association 2021 Rising Star!
Zymeworks is Proud of Two National Top Employer Recognitions Received in Canada, and Even Prouder of Our People Who Make Zymeworks Such a Great Place to Work!
.jpg?width=416&height=243&mode=crop)
.jpg?width=416&height=243&mode=crop)
.jpg?width=416&height=243&mode=crop)
